CY1112606T1 - Διαλυμα αριπριπραζολης για χορηγηση εκ του στοματος - Google Patents

Διαλυμα αριπριπραζολης για χορηγηση εκ του στοματος

Info

Publication number
CY1112606T1
CY1112606T1 CY20121100273T CY121100273T CY1112606T1 CY 1112606 T1 CY1112606 T1 CY 1112606T1 CY 20121100273 T CY20121100273 T CY 20121100273T CY 121100273 T CY121100273 T CY 121100273T CY 1112606 T1 CY1112606 T1 CY 1112606T1
Authority
CY
Cyprus
Prior art keywords
solution
aripriprazol
oral administration
acid
agents
Prior art date
Application number
CY20121100273T
Other languages
English (en)
Inventor
Prakash Parab
Joyce Chou
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112606(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1112606T1 publication Critical patent/CY1112606T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα ευρεσιτεχνία παρέχει φαρμακευτικό διάλυμα κατάλληλο για χορήγηση εκ του στόματος που περιλαμβάνει αριπιπραζόλη, φαρμακευτικώς κατάλληλο σύστημα διαλυτών, έναν ή περισσότερους παράγοντες ενίσχυσης/κάλυψης γεύσης και έναν ή περισσότερους παράγοντες που επιλέγονται από την ομάδα που αποτελείται από τα γαλακτικό οξύ, οξικό οξύ, τρυγικό οξύ και κιτρικό οξύ, όπου το εν λόγω διάλυμα έχει pΗ από 2,5 έως 4,5.
CY20121100273T 2001-04-25 2012-03-14 Διαλυμα αριπριπραζολης για χορηγηση εκ του στοματος CY1112606T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25
EP02723964A EP1381367B1 (en) 2001-04-25 2002-04-24 Aripiprazole oral solution

Publications (1)

Publication Number Publication Date
CY1112606T1 true CY1112606T1 (el) 2016-02-10

Family

ID=23099862

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100273T CY1112606T1 (el) 2001-04-25 2012-03-14 Διαλυμα αριπριπραζολης για χορηγηση εκ του στοματος

Country Status (37)

Country Link
US (1) US6977257B2 (el)
EP (2) EP1381367B1 (el)
JP (1) JP4401077B2 (el)
KR (1) KR100909329B1 (el)
CN (1) CN1512884B (el)
AR (1) AR033168A1 (el)
AT (1) ATE537831T1 (el)
AU (1) AU2002254722B2 (el)
BG (1) BG66177B1 (el)
BR (1) BR0208986A (el)
CA (1) CA2445276C (el)
CY (1) CY1112606T1 (el)
CZ (1) CZ306181B6 (el)
DK (1) DK1381367T3 (el)
EE (1) EE05581B1 (el)
ES (1) ES2377855T3 (el)
GE (1) GEP20053602B (el)
HK (2) HK1058316A1 (el)
HR (1) HRP20030870B1 (el)
HU (1) HU230456B1 (el)
IL (2) IL158202A0 (el)
IS (1) IS2863B (el)
MX (1) MXPA03009728A (el)
MY (1) MY129350A (el)
NO (1) NO324606B1 (el)
NZ (1) NZ528550A (el)
PE (1) PE20021086A1 (el)
PL (1) PL206882B1 (el)
PT (1) PT1381367E (el)
RS (1) RS52082B (el)
RU (1) RU2295960C2 (el)
SK (1) SK287948B6 (el)
TW (1) TWI337865B (el)
UA (1) UA76144C2 (el)
UY (1) UY27273A1 (el)
WO (1) WO2002085366A1 (el)
ZA (1) ZA200307797B (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
SI1542668T1 (sl) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
CA2540052C (en) * 2003-10-08 2012-04-10 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
CN1870980B (zh) * 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
JP4994043B2 (ja) * 2004-01-21 2012-08-08 エランコ・アニマル・ヘルス・アイルランド・リミテッド ミトラタピデ経口用溶液
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
CA2627693A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Wet granulation pharmaceutical compositions of aripiprazole
WO2007081367A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Dry formulations of aripiprazole
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
BRPI0815382A2 (pt) 2007-07-31 2015-02-10 Otsuka Pharma Co Ltd Métodos para a produção de suspensão de aripiprazol e formulação de secagem por congelamento
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
JP5664871B2 (ja) * 2009-06-19 2015-02-04 株式会社 メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
EP4327872A3 (en) 2011-03-18 2024-07-10 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846543B (zh) * 2011-06-27 2014-11-19 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
WO2014002553A1 (ja) 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
AU2013323435C1 (en) * 2012-09-26 2018-04-12 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban liquid formulations
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
EP2908859B1 (en) 2012-10-16 2017-05-17 Arven Ilac Sanayi ve Ticaret A.S. Aripiprazole formulations
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) † 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) † 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) † 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (el) * 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
WO1998043673A1 (en) * 1997-03-31 1998-10-08 Johnson & Johnson Consumer Companies, Inc. Solvent system for enhanced penetration of pharmaceutical compounds
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
JP2002524397A (ja) * 1998-09-03 2002-08-06 アルサイド コーポレーション 耐凍結性の局所用殺菌剤及びそれに関連する方法
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
IS6994A (is) 2003-10-14
CA2445276C (en) 2009-10-13
PL206882B1 (pl) 2010-10-29
SK12642003A3 (sk) 2004-07-07
MXPA03009728A (es) 2004-01-29
EP2436384B1 (en) 2015-06-10
HRP20030870A2 (en) 2004-06-30
NZ528550A (en) 2005-03-24
YU84703A (sh) 2006-08-17
GEP20053602B (en) 2005-08-10
RS52082B (sr) 2012-06-30
EP2436384A2 (en) 2012-04-04
MY129350A (en) 2007-03-30
TWI337865B (en) 2011-03-01
EP1381367B1 (en) 2011-12-21
IS2863B (is) 2013-12-15
NO20034705D0 (no) 2003-10-21
CZ306181B6 (cs) 2016-09-14
CZ20032821A3 (cs) 2004-09-15
US6977257B2 (en) 2005-12-20
EP2436384B2 (en) 2018-05-23
AU2002254722B2 (en) 2006-11-09
HU230456B1 (hu) 2016-07-28
CA2445276A1 (en) 2002-10-31
UA76144C2 (uk) 2006-07-17
SK287948B6 (sk) 2012-06-04
CN1512884B (zh) 2010-05-26
BG108216A (bg) 2004-12-30
PE20021086A1 (es) 2002-12-14
UY27273A1 (es) 2002-11-29
EE200300523A (et) 2004-02-16
HUP0303946A2 (hu) 2004-04-28
BG66177B1 (bg) 2011-11-30
IL158202A (en) 2008-04-13
IL158202A0 (en) 2004-05-12
EP1381367A1 (en) 2004-01-21
ZA200307797B (en) 2004-10-06
RU2295960C2 (ru) 2007-03-27
KR100909329B1 (ko) 2009-07-24
RU2003132426A (ru) 2005-04-20
ATE537831T1 (de) 2012-01-15
PT1381367E (pt) 2012-03-01
US20020193438A1 (en) 2002-12-19
HUP0303946A3 (en) 2005-06-28
NO324606B1 (no) 2007-11-26
AR033168A1 (es) 2003-12-03
HK1168792A1 (en) 2013-01-11
WO2002085366A1 (en) 2002-10-31
JP4401077B2 (ja) 2010-01-20
CN1512884A (zh) 2004-07-14
EE05581B1 (et) 2012-10-15
PL364666A1 (en) 2004-12-13
HK1058316A1 (en) 2004-05-14
DK1381367T3 (da) 2012-04-10
HRP20030870B1 (en) 2011-10-31
ES2377855T3 (es) 2012-04-02
NO20034705L (no) 2003-11-28
BR0208986A (pt) 2004-04-20
JP2004532225A (ja) 2004-10-21
EP2436384A3 (en) 2012-09-19
EP1381367A4 (en) 2009-07-01
KR20030096332A (ko) 2003-12-24

Similar Documents

Publication Publication Date Title
CY1112606T1 (el) Διαλυμα αριπριπραζολης για χορηγηση εκ του στοματος
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
CY1106802T1 (el) Ανασταλτικη της εκκρισης γαστρικου οξεος συνθεση
DE60128258D1 (de) Indanylderivate zur Behandlung von Atemwegserkrankungen
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
CY1108625T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση απο το στομα ηπαρινης ή παραγωγων της
TR200102385T2 (tr) Kendiliğinden çözülür N-benzoil staurosporin kompozisyonları.
HUP0203716A2 (hu) Tumorellenes hatású szubsztituált (N-benzil-indol-3-il)-glioxilsav-származékok, ezeket tartalmazó gyógyszerkészítmények
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
ATE534381T1 (de) Pharmazeutische cetp-inhibitor-zusammensetzungen
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
BR0002577A (pt) Suspensões orais de trovafloxacina
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
TR200202557T1 (tr) Esmolol formülasyonu
BR0104358A (pt) Formulações de taxana tendo solubilidade aperfeiçoada
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter